EBAC Accredited symposium held during Heart Failure 2016, Florence, Italy

View videorecording of lectures

 

Diabetes & Heart failure: Evaluating novel strategies to address outcomes

 

ESC Heart Failure Congress, Florence, Italy - May 21.
 

The educational objectives of this symposium were:

• Emphasize heart failure as a disease in which innovation is ongoing, yielding several new agents that are soon likely to change clinical practice
• To explore mechanisms and common pathways underlying the development of cardiovascular disease and heart failure and the particular risk of patients with diabetes
• To discuss the role of anti-diabetic therapy, in particular the use of SGLT2 inhibitors, in a risk-based intervention strategy that targets glucose control and cardiovascular risk factors
• To provide an expert perspective on the role of SGLT2 inhibitors in the treatment of patients with diabetes and heart failure
• To discuss current and future strategies for practical management of heart failure and interventions to prevent cardiovascular events

 

View lectures

 

Current treatment of Diabetes in Heart Failure

Patients with both HF and diabetes have poor prognosis. Prof. Adriaan Voors, Groningen, The Netherlands, reviews which currently available therapies provide benefit and which may increase risk in these patients.
​

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

Prof. David Fitchett, Toronto, Canada, discusses the results of the EMPA-REG OUTCOME trial: the first published trial evaluating CV endpoints with an SGLT2 inhibitor.
 

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

The results of the EMPA-REG outcome trial have changed views on how SGLT2 inhibition may yield benefit. Prof Naveed Sattar, Glasgow, United Kingdom, describes the emerging mechanistic concept based on the latest trial data.

Funding

This symposium was supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

In compliance with EBAC/ EACCME guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.

 

Other news from ESC Heart Failure 2016

News • 24-5-2016

One in four patients develop heart failure within four years of first heart attack

ESC HF 2016 Data from the UK based CALIBER programme reveal that risk factors include older age, socioeconomic deprivation, and diabetes.

News • 23-5-2016

No benefit of direct renin inhibitor in heart failure patients with diabetes

ESC HF 2016 Subgroup analysis of ATMOSPHERE fails to show a benefit of aliskiren as compared with enalapril in HF patients with diabetes. Combination therapy is associated with excess adverse events.

News • 23-5-2016

Flu jab associated with fewer hospitalisations in patients with heart failure

ESC HF 2016 Study ends controversy over influenza vaccination in heart failure patients and provides more robust evidence for current recommendations.

News • 23-5-2016

Exercise associated with longer life in patients with heart failure

ESC HF 2016 Individual patient data meta-analysis ExTraMATCH II shows that all patients benefited regardless of heart failure severity, age and gender.

News • 21-5-2016

Ten commandments on optimal management of heart failure

ESC HF 2016 At the presentation of the new ESC Heart Failure Guidelines, Professor Ponikowski, Chairperson of the guidelines Task Force, summarised the guidelines as ten commandments.

News • 21-5-2016

New ESC heart failure guidelines include distinct mid-range LVEF category

ESC HF 2016 A new ESC HF guideline was presented at the ESC Heart Failure Congress in Florence, and includes a new definition of HF, and updated treatment algorithms for chronic and acute HF.

3 minute education • 21-5-2016, ESC HF 2016, Florence, Italy, Adriaan Voors (Groningen, The Netherlands)

New 2016 ESC Heart Failure Guidelines

ESC HF 2016 Adriaan Voors, ESC Heart Failure Guideline Task Force Co-Chairman summarises the most important changes in the 2016 guideline presented in Florence at the ESC Heart Failure Congress today, as compared with the 2012 guidelines.